Exosome therapy of vitiligo

Investigating the safety and effectiveness of vitiligo treatment by injecting extracellular vesicles (exosome) derived from mesenchymal stem cells compared to fluocinolone IPA/50gr

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210228050535N7

Enrollment

Registered

2025-10-19

Start date

2025-11-21

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo. Vitiligo

Interventions

Intervention group: A dose of 2 mg of exosomes will be injected subcutaneously into the target area on one side, while fluocinolone will be administered on the opposite side..

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with bilateral vitiligo lesions Patients over 18 years of age

Exclusion criteria

Exclusion criteria: Patients under 18 years of age Patients receiving phototherapy at the same time at the test sites Pregnant or breastfeeding patients (self-reported) Patients who had surgery for vitiligo lesion interventions within the past 1 month Patients with a history of skin photosensitivity, cataracts, or skin cancers Patients who are psychologically unstable

Design outcomes

Primary

Measure	Time frame
Measurement of repigmentation dimensions. Timepoint: One month after injection. Method of measurement: by the physician.	—

Secondary

Measure	Time frame
Vitiligo Area Scoring Index (VASI). Timepoint: One month after injection. Method of measurement: As a percentage.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirali Khodashenas limoni

Mazandaran University of Medical Sciences

s.khodashenas@mazums.ac.ir+98 11 3354 3353

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026